A61K 2039/505
Comprising antibodies
Official title: {comprising antibodies}
A61K2039/505 (Comprising antibodies) appears on 19,429 US grants and 39,133 published applications in this corpus.
Search patents in A61K- Granted patents
- 19,429
- Published applications
- 39,133
- Assignees
- 7,095
- Inventors
- 46,577
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 6 | 0 |
| 1995 | 9 | 0 |
| 1996 | 19 | 0 |
| 1997 | 40 | 0 |
| 1998 | 84 | 0 |
| 1999 | 105 | 0 |
| 2000 | 143 | 0 |
| 2001 | 138 | 70 |
| 2002 | 179 | 565 |
| 2003 | 167 | 910 |
| 2004 | 190 | 855 |
| 2005 | 184 | 914 |
| 2006 | 284 | 815 |
| 2007 | 312 | 810 |
| 2008 | 380 | 839 |
| 2009 | 485 | 1145 |
| 2010 | 572 | 1135 |
| 2011 | 624 | 1212 |
| 2012 | 703 | 1209 |
| 2013 | 766 | 1176 |
| 2014 | 879 | 1466 |
| 2015 | 863 | 1524 |
| 2016 | 942 | 1725 |
| 2017 | 1033 | 1871 |
| 2018 | 1009 | 1887 |
| 2019 | 1112 | 2129 |
| 2020 | 1271 | 2216 |
| 2021 | 1231 | 2619 |
| 2022 | 1178 | 2567 |
| 2023 | 1105 | 2473 |
| 2024 | 1267 | 2881 |
| 2025 | 1295 | 2412 |
| 2026 | 842 | 1708 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors6 Oct 2026US 12,751,956 B2Hoffmann-La Roche Inc.
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-galectin 3 antibodies and their use in epilepsy and related diseases6 Oct 2026US 12,752,015 B2Sunmed Therapeutic Limited
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- Pharmaceutical combination for cancer treatment8 Oct 2026US 2026/0306466 A1Miyarisan Pharmaceutical Co., Ltd.
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Alk7 combination treatments8 Oct 2026US 2026/0306628 A1
- Nanoparticles for photoimmune therapy comprising photosensitizer and adjuvant, and usage thereof8 Oct 2026US 2026/0306632 A1Korea Institute of Science and Technology
- Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents8 Oct 2026US 2026/0306634 A1Wisconsin Alumni Research Foundation
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004